| Literature DB >> 30994773 |
Fatma Dilsad Oz1, Esra Ergin1, Simge Canatan1.
Abstract
OBJECTIVE: The aim of this randomized, controlled, prospective clinical trial was to evaluate the performances of two different universal adhesives and one etch-rinse adhesive for restoration of non-carious cervical lesions (NCCLs).Entities:
Mesh:
Substances:
Year: 2019 PMID: 30994773 PMCID: PMC6459227 DOI: 10.1590/1678-7757-2018-0358
Source DB: PubMed Journal: J Appl Oral Sci ISSN: 1678-7757 Impact factor: 2.698
Figure 1Materials used in the study
Distribution of treated research subjects and non-carious cervical lesions according to sex, age and education level
| Characteristics of research aubjects | Number of patients | Number of NCCLs (n%) |
|---|---|---|
|
| ||
| Male | 7 | 57 (36.7) |
| Female | 13 | 98 (63.2) |
| Education level | ||
| Primary School | 0 | - |
| High School | 8 | 60 (40) |
| Undergraduate education | 10 | 81 (50) |
| Graduate education | 2 | 14 (10) |
|
| ||
| 20-29 | 0 | - |
| 30-39 | 3 | 24 (15.4) |
| 40-49 | 8 | 64 (41.2) |
| 50-59 | 7 | 52 (33.5) |
| 60-65 | 2 | 15 (9.6) |
Distribution of non-cervical caries lesions (NCCLs) according to tooth type and arch
| Number of NCCLs | GSE | GSL | GER | ASE | ASL | AER | SBE | Total (n %) |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Maxillary | 13 | 13 | 13 | 16 | 17 | 14 | 15 | 101 (65.1) |
| Mandibular | 8 | 7 | 9 | 4 | 4 | 8 | 14 | 54 (34.8) |
|
| ||||||||
| Incisors | 2 | 3 | 2 | 3 | 1 | 7 | 5 | 23 (14.8) |
| Canines | 7 | 3 | 8 | 5 | 3 | 2 | 3 | 32 (20.6) |
| Premolars | 14 | 11 | 10 | 14 | 12 | 13 | 10 | 84 (54.1) |
| Molars | 2 | 1 | 2 | 1 | 3 | 3 | 4 | 16 (10.3) |
GSE: GLUMA Universal-self-etch; GSL: GLUMA Universal-selective etching; GER: GLUMA Universal-etch-and-rinse; ASE: All-Bond Universal-self-etch; ASL: All-Bond Universal-selective etching; AER: All-Bond Universal-etch-and-rinse; SBE: Single Bond2-etch-and-rinse
Characteristics of non-cervical caries lesions (NCCLs) included in the study
| Number of NCCLs (n) | |
|---|---|
|
| |
| <45 | |
| 45-90 | 40 |
| 90-135 | 93 |
| >135 | 22 |
|
| |
| <1.5 | 21 |
| 1.5-2.5 | 41 |
| >2.5-4.0 | 63 |
| >4.0 | 30 |
|
| |
| Absent | 131 |
| Present | 24 |
Clinical evaluation outcomes of different adhesive systems
| Evaluation criteria | Score | Baseline n (100%) | 6-month n (100%) | 12-month n (100%) | 24-month n (81.9%) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GSE | GSL | GER | ASE | ASL | AER | SBE | GSE | GSL | GER | ASE | ASL | AER | SBE | GSE | GSL | GER | ASE | ASL | AER | SBE | GSE | GSL | GER | ASE | ASL | AER | SBE | ||
| Retention | Alpha | 21 | 20 | 22 | 20 | 21 | 22 | 29 | 18* | 20 | 22 | 17* | 20 | 22 | 29 | 16* | 19 | 22 | 16* | 19 | 22 | 29 | 13* | 15 | 18 | 12* | 16 | 18 | 24 |
| -100 | -100 | -100 | -100 | -100 | -100 | -100 | (85.7) | -100 | -100 | -85 | (95.2) | -100 | -100 | (76.2) | -95 | -100 | -80 | (95.6) | -100 | -100 | (72.2) | (93.7) | -100 | -75 | (94.1) | -100 | -100 | ||
| Bravo | |||||||||||||||||||||||||||||
| Charlie | 3 | 3 | 1 | 5 | 1 | 4 | 1 | 5 | 1 | 4 | 1 | ||||||||||||||||||
| (14.3) | -15 | (4.8) | (23.8) | -5 | -20 | (4.8) | (27.8) | (6.3) | -25 | (5.9) | |||||||||||||||||||
| Marginal adaptation | Alpha | 20 (100) | 20 | 22 | 20 | 21 | 22 | 29 | 8* | 16 | 18 | 9* | 15 | 17 | 23 | 6* | 13* | 14* | 8* | 13* | 16* | 19* | 3* | 9* | 11* | 5* | 8* | 11* | 12* |
| -100 | -100 | -100 | -100 | -100 | -100 | (44.4) | -80 | (81.8) | (52.9) | -75 | (77.3) | (79.3) | (37.5) | (68.4) | (63.6) | -50 | -65 | (72.7) | (65.5) | (23.1) | -60 | (61.1) | (41.7) | -50 | (61.1) | -50 | |||
| Bravo | 10 | 4 | 4 | 8 | 5 | 5 | 6 | 10 | 6 | 8 | 8 | 7 | 6 | 10 | 10 | 6 | 7 | 7 | 8 | 7 | 12 | ||||||||
| (55.6) | -20 | (18.2) | (47.1) | -25 | (22.7) | (20.7) | (62.5) | (31.6) | (36.4) | -50 | -35 | (27.3) | (34.5) | (76.9) | -40 | (38.9) | (58.3) | -50 | (38.9) | -50 | |||||||||
| Charlie | |||||||||||||||||||||||||||||
| Marginal discoloration | Alpha | 20 (100) | 20 | 22 | 20 | 21 | 22 | 29 | 9* | 15 | 18 | 8* | 15 | 17 | 22 | 6* | 14* | 14* | 7* | 12* | 13* | 18* | 4* | 8* | 11* | 5* | 7* | 9* | 12* |
| -100 | -100 | -100 | -100 | -100 | -100 | -50 | -75 | (81.8) | (47.1) | -75 | (77.3) | (75.9) | (37.5) | (73.7) | (63.6) | (43.8) | -60 | (59.1) | (62.1) | (30.8) | (53.3) | (61.1) | (41.7) | (43.8) | -50 | -50 | |||
| Bravo | 9 | 5 | 4 | 9 | 5 | 5 | 7 | 10 | 5 | 8 | 9 | 8 | 9 | 11 | 9 | 7 | 7 | 7 | 9 | 9 | 12 | ||||||||
| -50 | -25 | (18.2) | (52.9) | -25 | (22.7) | (24.1) | (62.5) | (26.3) | (36.4) | (56.3) | -40 | (40.9) | (37.9) | (69.2) | (46.7) | (38.9) | (58.3) | (56.3) | -50 | -50 | |||||||||
| Charlie | |||||||||||||||||||||||||||||
| Postoperative sensitivity | Alpha | 20 (100) | 20 | 22 | 20 | 21 | 22 | 29 | 18 | 20 | 22 | 17 | 19 | 22 | 29 | 16 | 19 | 22 | 16 | 19 | 22 | 29 | 13 | 15 | 18 | 12 | 16 | 18 | 24 |
| -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -95 | -100 | -100 | -100 | -100 | -100 | -100 | -95 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | |||
| Bravo | 1 | 1 | |||||||||||||||||||||||||||
| Charlie | |||||||||||||||||||||||||||||
| Secondary caries | Alpha | 20 (100) | 20 | 22 | 20 | 21 | 22 | 29 | 18 | 20 | 22 | 17 | 20 | 22 | 29 | 16 | 19 | 22 | 16 | 20 | 22 | 29 | 13 | 15 | 18 | 12 | 16 | 18 | 24 |
| -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | -100 | |||
| Bravo | |||||||||||||||||||||||||||||
| Charlie |
(*) indicates significant difference within each group when compared to baseline (p<0.05), GSE: Gluma Universal- self-etch, GSL: GLUMA Universal-selective etching, GER: GLUMA Universal-etch-and-rinse, ASE: All-Bond Universal-self-etch, ASL: All-Bond Universal-selective etching, AER: All-Bond Universal-etch-and-rinse, SBE: Single Bond2-etch-and-rinse
Relative cumulative frequencies (%) of lost restorations during 24-month follow-up
| 6-month | 12-month | 24-month | |
|---|---|---|---|
| GSE | 14.3a* | 23.8a* | 27.8a* |
| GSL | 0.0b | 5b | 6.3b |
| GER | 0.0b | 0.0b | 0.0b |
| ASE | 15.0a* | 20a* | 25a* |
| ASL | 4.8b | 4.8b | 5.9b |
| AER | 0.0b | 0.0b | 0.0b |
| SBE | 0.0b | 0.0b | 0.0b |
(*) indicates significant difference within each group when compared to baseline
Different superscripts show significant differences at columns (p<0.05)
Figure 2Flowchart of the study. nP: number of patients; nR: number of restorations; GSE: GLUMA Universal-self-etch; GSL: GLUMA Universal-selective etching; GER: GLUMA Universal-etch-and-rinse; ASE: All-Bond Universal-self-etch; ASL: All-Bond Universal-selective etching; AER: All-Bond Universal-etch-and-rinse; SBE: Single Bond2-etch-and-rinse